Zobrazeno 1 - 10
of 95
pro vyhledávání: '"J M, Tourani"'
Autor:
Y, Tao, J, Biau, X S, Sun, C, Sire, L, Martin, M, Alfonsi, J B, Prevost, A, Modesto, C, Lafond, J M, Tourani, J, Miroir, M C, Kaminsky, A, Coutte, X, Liem, E, Chautard, E, Vauleon, F, Drouet, A, Ruffier, J F, Ramee, G, Waksi, A, Péchery, M, Wanneveich, J, Guigay, A, Aupérin, J, Bourhis
Publikováno v:
Annals of Oncology
Annals of Oncology, 2022, ⟨10.1016/j.annonc.2022.10.006⟩
Annals of Oncology, 2022, ⟨10.1016/j.annonc.2022.10.006⟩
To evaluate potential synergistic effect of pembrolizumab with radiotherapy (RT) compared with a standard-of-care (SOC) cetuximab-RT in patients with locally advanced-squamous cell carcinoma of head and neck (LA-SCCHN).Patients with nonoperated stage
Autor:
Sylvain Ladoire, Valerie Perrot, L. Zara, Delphine Topart, E. Meriaux, B. Laguerre, Lionnel Geoffrois, Marine Gross-Goupil, Loic Mourey, Philippe Barthélémy, Aude Flechon, Antoine Thiery-Vuillemin, Stéphane Oudard, J-M. Tourani, Bernard Escudier, Laurence Albiges, Gwenaelle Gravis
Publikováno v:
Annals of Oncology. 32:S694-S695
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Médecine Nucléaire. 33:718-723
Resume Les tumeurs endocrines digestives constituent un groupe tres heterogene de tumeurs de pronostic tres different. Il est important de distinguer les tumeurs endocrines bien differenciees (tumeurs carcinoides du tube digestif et tumeurs endocrine
Autor:
M. Kazatchkine, P. Espinoza, C. Audrouin, A. Le Tourneau, Josée Audouin, F. Carnot, J. M. Andrieu, Jacques Diebold, I. Bouchard, S. Prevot, J. M. Tourani
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb43608d554d0a1609acee15e6553979
https://doi.org/10.1159/000419826
https://doi.org/10.1159/000419826
Publikováno v:
British Journal of Cancer
Geertsen, P F, Gore, M E, Negrier, S, Tourani, J M & Maase, H V D 2004, ' Safety and efficacy of subcutaneous and continuous intravenous infusion of rIL-2 in patients with metastatic renal cell carcinoma ', B J C, vol. 90, no. 6, pp. 1156-1162 . https://doi.org/10.1038/sj.bjc.6601709
Geertsen, P F, Gore, M E, Negrier, S, Tourani, J M & Maase, H V D 2004, ' Safety and efficacy of subcutaneous and continuous intravenous infusion of rIL-2 in patients with metastatic renal cell carcinoma ', B J C, vol. 90, no. 6, pp. 1156-1162 . https://doi.org/10.1038/sj.bjc.6601709
A retrospective analysis was conducted on data from four open-label, nonrandomised, phase II trials of recombinant interleukin-2 (rIL-2) in patients with metastatic renal cell carcinoma to compare the safety and efficacy of administration by subcutan
Autor:
François Guilhot, L. Sensebe, Norbert Ifrah, Bernard Desablens, S Brahimi, Pierre Colonna, P. Y. Leprise, M Belhani, R Levy, J M Tourani
Publikováno v:
Journal of Clinical Oncology. 10:1086-1094
PURPOSE For patients with Hodgkin's disease (HD) who do not achieve complete response (CR), who experience a relapse within the first year of CR, and for those who have two or more relapses, the outcome is poor. Salvage chemotherapy regimens at conve
Publikováno v:
Journal of Hepatology. 12:36-39
Acute hepatitis is a potential, although rare, complication following administration of high doses of Etoposide (VP 16-213). We report three cases of severe hepatocellular necrosis following administration of standard doses of this antineoplastic age
Autor:
X, Breton, P, Corbi, J P, Faure, C, Jayle, J P, Richer, J C, Meurice, J M, Tourani, J L, Kraimps
Publikováno v:
Annales de chirurgie. 127(3)
Assessment of laparoscopic adrenalectomy in the management of operable non-small cell lung cancer (NSCLC) associated with solitary and synchronous adrenal mass.In a retrospective study, we reviewed 3 patients with operable NSCLC proved by pulmonary b